These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35266525)

  • 1. Tapering subcutaneous methotrexate causes more disease flares compared with tapering oral administration in established rheumatoid arthritis patients.
    Looijen AEM; van Mulligen E; van der Helm-van Mil AHM; de Jong PHP
    Rheumatology (Oxford); 2022 Aug; 61(8):e216-e218. PubMed ID: 35266525
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials.
    Park JK; Kim MJ; Choi Y; Winthrop K; Song YW; Lee EB
    Clin Rheumatol; 2020 Feb; 39(2):375-379. PubMed ID: 31823141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.
    Subesinghe S; Scott IC
    Expert Rev Clin Pharmacol; 2015; 8(6):751-60. PubMed ID: 26289226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
    Schiff M; Jaffe J; Freundlich B; Madsen P
    Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
    Schiff MH; Sadowski P
    Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate revisited: considerations for subcutaneous administration in RA.
    Jay R
    Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
    Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Genovese MC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Finck BK
    N Engl J Med; 2000 Nov; 343(22):1586-93. PubMed ID: 11096165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
    Alsaeedi S; Keystone EC
    Nat Rev Rheumatol; 2014 Oct; 10(10):578-9. PubMed ID: 25090946
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice.
    Vidal-Montal P; Thomas M; Combier A; Steelandt A; Miceli-Richard C; Molto A; Narváez J; Nolla JM; Allanore Y; Avouac J
    Joint Bone Spine; 2023 Dec; 90(6):105620. PubMed ID: 37482177
    [No Abstract]   [Full Text] [Related]  

  • 13. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
    Raghu P; Grover PS; Kumar A
    Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
    Bianchi G; Caporali R; Todoerti M; Mattana P
    Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
    Yadlapati S; Efthimiou P
    Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.
    Goodman SM; Bykerk VP; DiCarlo E; Cummings RW; Donlin LT; Orange DE; Hoang A; Mirza S; McNamara M; Andersen K; Bartlett SJ; Szymonifka J; Figgie MP
    J Rheumatol; 2018 May; 45(5):604-611. PubMed ID: 29545451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China.
    Hu D; Bao C; Chen S; Gu J; Li Z; Sun L; Han X; Ni L
    Rheumatol Int; 2009 Jan; 29(3):297-303. PubMed ID: 18704426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.